Immunotherapy

Overview

Immunotherapy harnesses the patient's own immune system to fight disease, most notably cancer. Immune checkpoint inhibitors (ICIs) — antibodies that block PD-1, PD-L1, or CTLA-4 — have revolutionized oncology since their introduction in the 2010s, producing durable responses in melanoma, lung cancer, renal cell carcinoma, and other malignancies. However, only 20-40% of patients respond to ICIs, and the search for response predictors has converged on an unexpected target: the gut microbiome.

In the WikiBiome framework, immunotherapy sits at the intersection of immune balance, microbial biomarkers, and metal-dependent immune regulation. The microbiome determines whether the immune system can be effectively unleashed against tumors, and metal status modulates both immune checkpoint expression and microbial community composition.

The Microbiome Determines Immunotherapy Response

Landmark Observations

Multiple independent studies have demonstrated that gut microbiome composition predicts ICI response:

  • Responders harbor distinct microbial communities enriched in specific taxa
  • Germ-free mice do not respond to anti-PD-1 therapy
  • Fecal microbiota transplant (FMT) from responders to non-responders can convert non-responders to responders
  • Antibiotic use before ICI therapy dramatically reduces response rates and survival

Responder-Associated Taxa

TaxonICI TypeEvidence
faecalibacterium prausnitziiAnti-PD-1Butyrate production; Treg induction
bifidobacteriumAnti-PD-L1DC maturation; enhanced T cell priming
akkermansia muciniphilaAnti-PD-1Barrier integrity; IL-12 signaling
RuminococcaceaeAnti-CTLA-4SCFA production
bacteroides fragilis (non-toxigenic)Anti-CTLA-4Polysaccharide A-driven Th1 response

Non-Responder-Associated Taxa

Mechanisms of Microbiome-Immunotherapy Interaction

SCFA-Mediated Immune Priming

short chain fatty acids, especially butyrate, prime anti-tumor immunity through hayase 2021 intestinal microbiome metabolites immune checkpoint cancer:

  • Butyrate enhances CD8+ T cell effector function through epigenetic modification (HDAC inhibition)
  • Propionate promotes memory T cell formation
  • SCFAs calibrate the Treg/effector T cell balance in the gut-associated lymphoid tissue (GALT)

Bile Acid Signaling

Microbial bile acid metabolites modulate anti-tumor immunity:

  • Secondary bile acids activate NKT cells in the liver
  • Bile acid composition affects dendritic cell function and antigen presentation
  • Statin-induced bile acid changes (see statins) could theoretically influence ICI response

Virome Contribution

The gut virome also predicts ICI response liu 2026 gut virome anti pd1 nsclc:

  • Specific bacteriophage populations correlate with anti-PD-1 response in NSCLC
  • Phage-mediated bacterial lysis may release tumor-associated antigens that prime cross-reactive immune responses
  • Phage composition reflects and modulates bacterial community structure

Metal Connections

Metals in Immune Checkpoint Regulation

Metal homeostasis influences immune checkpoint expression:

  • zinc: Zinc deficiency impairs T cell function and may increase PD-1 expression on exhausted T cells
  • copper: Copper accumulates in the tumor microenvironment and promotes immunosuppressive M2 macrophage polarization (cuproptosis)
  • iron: Iron-loaded macrophages in the tumor microenvironment suppress anti-tumor immunity; ferroptosis can release tumor antigens
  • selenium: Selenoproteins are required for optimal T cell proliferation and effector function

Calprotectin as Response Biomarker

calprotectin — the zinc/manganese-sequestering protein central to nutritional immunity — is being explored as an immunotherapy response biomarker. Fecal calprotectin levels correlate with gut inflammation status and may predict ICI-induced colitis.

Metal-Dependent Microbial Metabolites

The microbiome's immunomodulatory output depends on metal-requiring enzymes:

  • SCFA production requires iron-sulfur cluster-containing enzymes in butyrate-producing bacteria
  • Indole production (via tryptophanase) requires pyridoxal phosphate, whose availability is metal-regulated
  • siderophores metallophores from gut bacteria can directly modulate immune cell function

Immunotherapy-Related Adverse Events

ICI therapy frequently causes immune-related adverse events (irAEs), most commonly colitis. The microbiome predicts irAE risk:

  • Patients with higher pre-treatment bacteroidetes abundance have lower colitis risk
  • Patients with higher Firmicutes/Bacteroidetes ratio have higher colitis risk
  • The same butyrate-producing bacteria that promote ICI response also protect against colitis
  • Microbiome-targeted interventions could potentially reduce irAEs without compromising anti-tumor efficacy

Clinical Implications

  • Pre-treatment microbiome profiling could stratify patients into likely responders and non-responders
  • Antibiotic stewardship: Avoiding unnecessary antibiotics before ICI therapy
  • FMT: Clinical trials of FMT to convert non-responders (NCT03341143, NCT04116775)
  • Dietary intervention: High-fiber diets increase SCFA-producing bacteria and may enhance ICI response
  • Metal supplementation: Correcting zinc and selenium deficiency before ICI therapy

Open Questions

  • Can a standardized microbiome panel predict ICI response with clinical-grade accuracy?
  • Does metal status (Zn, Se, Fe, Cu) independently predict ICI response or modify microbiome-mediated effects?
  • Can phage therapy selectively remove non-responder-associated taxa?
  • Will combination strategies (ICI + FMT + dietary intervention) become standard of care?

Cross-References

Related Articles